Terazosin Effect on Cardiac Changes in Early Parkinson's Disease

Last updated: November 22, 2024
Sponsor: Cedars-Sinai Medical Center
Overall Status: Active - Recruiting

Phase

2

Condition

Sleep Disorders

Treatment

Terazosin

Clinical Study ID

NCT04386317
Study#000540
  • Ages 50-85
  • All Genders

Study Summary

Parkinson's disease (PD) is characterized by many non-motor symptoms that occur several years before the diagnosis, in particular idiopathic REM behavior disorder (iRBD), which is associated with autonomic impairment. The purpose of this study is to investigate the effect of treatment with the selective post-synaptic a1-adrenergic blocker terazosin on 123I-MIBG myocardial uptake in a population of subjects with defined pre-motor PD risks (i.e. hyposmia and RBD) and abnormal baseline 123I-MIBG uptake, with or without 123I-Ioflupane uptake abnormality or PD motor symptoms. Scintigraphic changes will be correlated to motor and non-motor severity of PD, measured by validated clinical scales and cardiac autonomic function tests.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Male or female of age between 50 and 85 years at time of enrollment.

  • Diagnosis of idiopathic REM sleep behavior disorder (iRBD), established either as 'definite RBD' according to the criteria proposed by the InternationalClassification of Sleep Disorders (ICSD)-2 [AASM, 2005] or 'probable RBD' followinga score of 6 or higher in the RBD questionnaire (RBDSQ) [Nomura et al, 2011], with ascore of at least 1 in subitems 6.1 to 6.4 of question 6 [Halsband et al, 2018].

  • At least one of the following:

  1. Diagnosis of hyposmia, established as a University of Pennsylvania SmellIdentification Test (UPSIT) score < 20th percentile for the individual's agegroup and sex.

  2. Functional constipation assessed by a scores > 4 on a questionnaire based onmodified ROME IV diagnostic criteria.

  3. Color vision abnormality, as assessed using HRR Pseudoisochromatic Plates, inthe absence of congenital dyschromatopsia

  4. Symptoms of depression, as assessed by a Beck Depression Inventory (BDI) fastscreen score >3 or concurrent use of antidepressant medications.

  • Abnormal 123I-MIBG myocardial scintigraphy, as defined by a Late H/M ratio < 2.2and/or a WR >20%, with normal cardiac ejection fraction (LVEF >55%).

  • Capacity to give informed consent

Exclusion

Exclusion Criteria:

  • Secondary Parkinsonism, including tardive

  • Concurrent dementia defined by a score lower than 22 on the MOCA

  • Concurrent severe depression defined by a BDI fast screen score greater than 13

  • Comorbidites related to SNS hyperactivity

  • Heart failure (LVEF< 45%)

  • Recent myocardial revascularization (< 12 weeks)

  • Hypertension (SBP >150 mmHg or DBP> 100mmHg)

  • Chronic Atrial fibrillation

  • Concurrent use of Alpha- adrenergic antagonist

  • Diabetes mellitus

  • COPD

  • Untreated Severe Sleep Apnea; Apnea-Hypopnea Index (AHI) > 30/h.

  • Contraindication to the use of Terazosin

  • Recent myocardial infarction (< 48 h)

  • Ongoing angina pectoris

  • Cardiogenic shock or prolonged

  • Breast feeding

  • Current use of Phosphodiesterase type 5 inhibitors: sildenafil (Viagra TM),tadalafil (Cialis TM), or vardenafil (Levitra TM)

  • History of Priapism

  • Neurogenic orthostatic hypotensiondefiened as symptomatic decrease in BP> 20mmHg systolic or > 10mmHg diastolic and HR increase < 20bpm on supine tositting or standing

  • Blood pressure less than 110 mmHG systolic at screening or baseline visit

  • Use of investigational drugs whitin 30 days before screening

  • For female participant, Pregnacy, or plans for child-bearing during studyperiod

  • Allergy/hypersenstivity to iodine or study medication

Study Design

Total Participants: 15
Treatment Group(s): 1
Primary Treatment: Terazosin
Phase: 2
Study Start date:
November 01, 2020
Estimated Completion Date:
December 30, 2025

Study Description

Based on the increased risk to develop PD, individuals with iRBD are currently considered ideal candidates for therapies that can possibly protects brain cells, due to the critical window of opportunity to intervene early before brain cell loss progresses significantly.

Early changes of PD are associated with a number of symptoms including loss of smell, constipation, anxiety and depression. In addition, early heart and brain abnormalities can be visualized using specialized imaging techniques called 123I-MIBG myocardial scintigraphy (MIBG) and dopamine transporter (DAT) single photon emission computerized tomography (SPECT) respectively. The combined presence of certain symptoms and the use of these imaging techniques are considered early markers of PD in individuals with iRBD.

In this study the investigators want to learn about the effect of treatment with the adrenergic blocker terazosin on MIBG abnormalities in iRBD patients at risk to develop PD. The investigators believe that reversing the MIBG abnormality might prelude to a slowing of the neurodegenerative process. This drug is approved by the U.S. Food and Drug Administration (FDA) for Benign Prostatic Hyperplasia (BPH) and Hypertension. However, terazosin is not approved by the FDA in patients with iRBD at risk for PD. The available doses for this drug oral formulations are 1mg, 2 mg, 5mg and 10 mg.

Changes visualized with the MIBG imaging technique will be correlated to the presence and severity of neurological (i.e. tremors, stiffness, slow movements, walking difficulties) and other symptoms associated with PD (i.e. abnormal smell, constipation, depression, color vision abnormalities), as measured by specific clinical scales and exams.

Connect with a study center

  • Cedars Sinai Medical Center

    Los Angeles, California 90048
    United States

    Active - Recruiting

  • Michele L Lima Gregorio

    Los Angeles, California 90046
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.